Business Wire

Desktop Health™ Introduces the PrintRoll™ Rotating Build Platform for the 3D-Bioplotter® — a First-of-its-kind Bioprinting Tool to Develop Tubular Solutions for Vascular, Digestive, Respiratory, and Other Channels

24.7.2023 15:30:00 EEST | Business Wire | Press release

Share

Desktop Health — the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. (NYSE: DM) — today announced a breakthrough in bioprinting with the launch of PrintRoll™, an innovative rotating build platform that can produce intelligent tubular solutions for the body’s vascular, digestive, respiratory, and reproductive channels on the 3D-Bioplotter premier bioprinting system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230724680554/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health, examines two tubular medical devices printed on the new 3D-Bioplotter® PrintRoll™ rotating build platform in medical-grade materials. PrintRoll is designed to enable new medical solutions for the body’s thousands of miles of internal channels, such as vascular, digestive, and other systems. (Photo: Business Wire)

The 3D-Bioplotter is a highly sophisticated extrusion-based 3D printer that processes liquids, melts, pastes, gels, or other materials, including cells, through a needle tip on a Swiss-made, 3-axis gantry system with high accuracy and temperature, sterility, and design controls. 3D-Bioplotter offers eight printheads with the widest range of temperatures in bioprinting — from 2°C to 500°C (35.6°F to 932°F) — enabling complex, multi-material medical parts.

The PrintRoll add-on feature has been in development since 2019 as part of a collaboration with Johannes Gutenberg University Mainz, a public research university in Mainz, Germany.

“We are proud to offer the first bioprinting tool specifically designed to develop medical solutions for the thousands of miles of channels found in the human body,” said Ric Fulop, Founder and CEO of Desktop Metal. “Desktop Health exists to deliver 3D printing solutions that improve patient lives, and we are confident that PrintRoll, offered exclusively on the 3D-Bioplotter, will enable all-new regenerative innovations. We look forward to seeing what our customers will create next with this exciting new tool.”

Visit TeamDM.com/3DBioplotterBrochure to see a video of the PrintRoll in action and download the latest 3D-Bioplotter brochure, which chronicles 20+ years of innovations on the bioprinter by regenerative medicine experts.

How PrintRoll Works

The PrintRoll platform attaches to the modular build plate of the 3D-Bioplotter and features a motor-driven rotating mandrel with spring-loaded, easily exchangeable drums of different sizes. Rotating speed is tightly controlled by the 3D-Bioplotter’s easy-to-use software.

As the PrintRoll tool rotates, the printhead moves back and forth depositing material on the surface in the desired design. For example, polycaprolactone (PCL), a medical-grade, biodegradable plastic used in many FDA-cleared implants and devices, hardens quickly on the drum after the melted material is printed. In bioprinting, users typically produce a structure or scaffold in a stiff or flexible biocompatible material that is designed to repair and integrate with cells of the body, sometimes degrading after a certain period of time.

The PrintRoll comes with a 10 mm diameter drum – with 20 mm and 40 mm sizes available – designed to accommodate the development of solutions for a variety of human channels, which vary based on age and gender. Standard diameter sizes generally correspond to the diameters of the femoral artery (~10 mm), trachea (~10-20 mm), fallopian tube (~5-15 mm), aorta (~25 mm) esophagus (~30 mm), and a range of intestine segments (~40-100 mm).

The PrintRoll system supports printing hollow cylindrical structures up to 140 mm in length, depending on the printhead used. Custom sizes may also be available.

“Up until now, the creation of thin-walled cylindrical devices with complex structured walls has been challenging to accomplish with regenerative materials, such as hydrogels,” said Nicole Black, Ph.D., VP of Biomaterials and Innovation at Desktop Health. “With the PrintRoll, materials are patterned directly on top of a substrate that rolls as the printhead also moves, supporting the deposited layers and therefore expanding the palette of materials that can be 3D printed into these important structures. Following printing, devices can be removed from the PrintRoll, leaving high-resolution and reproducible parts that customers have come to expect from the 3D-Bioplotter.”

The PrintRoll comes with a library of honeycomb designs and standard printing parameters for common materials. The PrintRoll platform, which is compatible with 4th Generation 3D-Bioplotter models, is available for pre-order now, with shipping expected in the fourth quarter. Contact Desktop Health to learn more at TeamDM.com/3DBioplotterMoreInfo .

3D-Bioplotter® Continues Pioneering Bioprinting

PrintRoll continues the long history of bioprinting innovations on the world’s most researched bioprinting system, as detailed in the last 3D-Bioplotter brochure.

This tradition is also continued with CMFlex™ — the first 3D printed regenerative bone graft substitute product cleared by the FDA and the first such clearance based on manufacturing on the 3D-Bioplotter. Developed by Dimension Inx, CMFlex is an easy-to-use flexible bone graft product that is 3D printed on a standard 3D-Bioplotter Manufacturer model. This new product is an alternative to an autograft, in which a physician intrusively harvests bone from one area of a patient’s body to repair damaged or diseased bone elsewhere in the body.

“The recent FDA clearance of CMFlex by Dimension Inx is a breakthrough for the field of additive, regenerative medicine – one that clearly showcases the robustness of the 3D-Bioplotter,” said Lou Azzarra, President of Desktop Health. “Commercial milestones like this often take many years, and we congratulate the entire team at Dimension Inx on this achievement.”

Visit TeamDM.com/3DBioplotterBrochure to download our latest brochure, which details how Dimension Inx developed CMFlex for commercialization.

About Desktop Metal

Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products. Our innovative 3D printers, materials, and software deliver the speed, cost, and part quality required for this transformation. We’re the original inventors and world leaders of the 3D printing methods we believe will empower this shift, binder jetting and digital light processing. Today, our systems print metal, polymer, sand and other ceramics, as well as foam and recycled wood. Manufacturers use our technology worldwide to save time and money, reduce waste, increase flexibility, and produce designs that solve the world’s toughest problems and enable once-impossible innovations. Learn more about Desktop Metal and our #TeamDM brands at www.desktopmetal.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

_______________________
1“Hence, 3D Bioplotter® which was capable of cell-laden bioprinting, could be defined as the first commercial 3D bioprinter in the world.” Gu Z, Fu J, Lin H, He Y. Development of 3D bioprinting: From printing methods to biomedical applications. Asian J Pharm Sci. 2020 Sep;15(5):529-557. doi: 10.1016/j.ajps.2019.11.003. Epub 2019 Dec 17. PMID: 33193859; PMCID: PMC7610207. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610207/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Sarah Webster
sarahwebster@desktopmetal.com
(313) 715-6988

Investor Relations:
Jay Gentzkow
jaygentzkow@desktopmetal.com
(781) 730-2110

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa

TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 17:33:00 EEST | Press release

TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and maintain continuity ahead of such events.” Using the current Middle East crisis as a lens, where Gulf hubs carry roughly 14 percent of global transit traffic, the r

The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 16:00:00 EEST | Press release

Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or leaves, the subscription keeps running, with no swapping cards and no missed payments. Cover a one-time purchase. Issue a virtual card for a single transaction like event r

Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 15:30:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity is not limited to predictable travel peaks, with organized fraud rings continuously adjusting their methods throughout the year. Riskified's travel n

PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 14:54:00 EEST | Press release

PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets under management and achieved an annualized total shareholder return of 5.8% since 2017. Total shareholder return in 2025 was positively driven by increased dividends from portfolio companies and returns from financial investments. It was also impacted by downward movements in the valuations of some assets, as a result of wider market conditions, an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye